Logo
E

Enliven Therapeutics

65 employees

Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies.

Investor insights

Funding rounds participated in

$90M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2019

Funding rounds raised

Total raised

$90M

from investors over 1 rounds

E

Enliven Therapeutics raised $90M on April 19, 2024

FAQ